Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling

Introduction Annexin A1 (ANXA1) is an anti-inflammatory protein reported to play a role in cell proliferation and apoptosis, and to be deregulated in breast cancer. The exact role of annexin A1 in the biology of breast cancer remains unclear. We hypothesized that the annexin A1 plays an oncogenic role in basal subtype of breast cancer by modulating key growth pathway(s). Methods By mining the Cancer Genome Atlas (TCGA)-Breast Cancer dataset and manipulating annexin A1 levels in breast cancer cell lines, we studied the role of annexin A1 in breast cancer and underlying signaling pathways. Results Our in-silico analysis of TCGA-breast cancer dataset demonstrated that annexin A1 mRNA expression is higher in basal subtype compared to luminal and HER2 subtypes. Within the basal subtype, patients show significantly poorer overall survival associated with higher expression of annexin A1. In both TCGA patient samples and cell lines, annexin A1 levels were significantly higher in basal-like breast cancer than luminal and Her2/neu-positive breast cancer. Stable annexin A1 knockdown in TNBC cell lines suppressed the mTOR-S6 pathway likely through activation of AMPK but had no impact on the MAPK, c-Met, and EGFR pathways. In a cell migration assay, annexin A1-depleted TNBC cells showed delayed migration as compared to wild-type cells, which could be responsible for poor patient prognosis in basal like breast cancers that are known to express higher annexin A1. Conclusions Our data suggest that annexin A1 is prognostic only in patients with basal like breast cancer. This appears to be in part due to the role of annexin A1 in activating mTOR-pS6 pathway.

[1]  T. Pandita,et al.  Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers , 2014, Oncotarget.

[2]  C. Betz,et al.  Where is mTOR and what is it doing there? , 2013, The Journal of cell biology.

[3]  Peijing Zhang,et al.  Deubiquitination and stabilization of PTEN by USP13 , 2013, Nature Cell Biology.

[4]  M. Sun,et al.  Potential role of Anxa1 in cancer. , 2013, Future oncology.

[5]  Somchai Yodsanga,et al.  Ribosomal Protein S6 Phosphorylation is Associated with Epithelial Dysplasia and Squamous Cell Carcinoma of the Oral Cavity , 2013, Pathology & Oncology Research.

[6]  L. Kirshenbaum,et al.  Bidirectional Regulation of Nuclear Factor-&kgr;B and Mammalian Target of Rapamycin Signaling Functionally Links Bnip3 Gene Repression and Cell Survival of Ventricular Myocytes , 2013, Circulation. Heart failure.

[7]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[8]  Sung-Wuk Jang,et al.  The role of annexin A1 in expression of matrix metalloproteinase-9 and invasion of breast cancer cells. , 2012, Biochemical and biophysical research communications.

[9]  D. Noh,et al.  Clinical Significance of Annexin A1 Expression in Breast Cancer , 2011, Journal of breast cancer.

[10]  C. Parent,et al.  TOR kinase complexes and cell migration , 2011, The Journal of cell biology.

[11]  S. Leow,et al.  Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis , 2011, Oncogene.

[12]  C. Walker,et al.  The role of LKB1 and AMPK in cellular responses to stress and damage , 2011, FEBS letters.

[13]  Sylvia E. Le Dévédec,et al.  Annexin A1 regulates TGF-β signaling and promotes metastasis formation of basal-like breast cancer cells , 2010, Proceedings of the National Academy of Sciences.

[14]  G. Mills,et al.  ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS , 2010, Proceedings of the National Academy of Sciences.

[15]  R. Shaw,et al.  LKB1 and AMP‐activated protein kinase control of mTOR signalling and growth , 2009, Acta physiologica.

[16]  T. Putti,et al.  Annexin-1 Regulates Growth Arrest Induced by High Levels of Estrogen in MCF-7 Breast Cancer Cells , 2009, Molecular Cancer Research.

[17]  Yun Wu,et al.  Loss of Annexin A1 Expression in Breast Cancer Progression , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[18]  Shile Huang,et al.  Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins , 2008, Oncogene.

[19]  Y. Yang,et al.  Decreased Expression of Annexin A1 during the Progression of Cervical Neoplasia , 2008, The Journal of international medical research.

[20]  L. Platanias,et al.  CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. , 2008, Blood.

[21]  Y. Jeng,et al.  Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma , 2008, Journal of surgical oncology.

[22]  R. Lackman,et al.  Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy , 2008, Modern Pathology.

[23]  R. Kaur,et al.  GATA Factors and Androgen Receptor Collaborate To Transcriptionally Activate the Rhox5 Homeobox Gene in Sertoli Cells , 2008, Molecular and Cellular Biology.

[24]  G. Murray,et al.  Characterisation and protein expression profiling of annexins in colorectal cancer , 2007, British Journal of Cancer.

[25]  Shazib Pervaiz,et al.  Annexin 1: the new face of an old molecule , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  David Chia,et al.  Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. , 2006, Human pathology.

[27]  J. Blenis,et al.  Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways , 2006, Oncogene.

[28]  D. Burggraf,et al.  Matrix metalloproteinase‐9 promotes neutrophil and T cell recruitment and migration in the postischemic liver , 2006, Journal of leukocyte biology.

[29]  A. Wong,et al.  Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. , 2006, Endocrinology.

[30]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[31]  F. Kokocinski,et al.  Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development , 2006, Oncogene.

[32]  Yuval Dor,et al.  Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. , 2005, Genes & development.

[33]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[34]  M. Crouch,et al.  Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration , 2004 .

[35]  Fang Liu,et al.  Overexpression of annexin 1 in pancreatic cancer and its clinical significance. , 2004, World journal of gastroenterology.

[36]  L. Lund,et al.  MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum , 2003, Molecular and Cellular Neuroscience.

[37]  U. Rescher,et al.  Intact Ca(2+)-binding sites are required for targeting of annexin 1 to endosomal membranes in living HeLa cells. , 2000, Journal of cell science.

[38]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[39]  J. Huh,et al.  Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. , 2000, European journal of biochemistry.

[40]  G. Thomas,et al.  Ribosomal S6 kinase signaling and the control of translation. , 1999, Experimental cell research.

[41]  Jie Chen,et al.  The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression* , 1999, The Journal of Biological Chemistry.

[42]  Tao Yan,et al.  Overexpression of Manganese Superoxide Dismutase Suppresses Tumor Necrosis Factor-induced Apoptosis and Activation of Nuclear Transcription Factor-κB and Activated Protein-1* , 1998, The Journal of Biological Chemistry.

[43]  S. Schreiber,et al.  Translation control: Connecting mitogens and the ribosome , 1998, Current Biology.

[44]  M. Toth,et al.  Elevated Levels of Annexin I Protein in vitro and in vivo in Rat and Human Mammary Adenocarcinoma , 1998, Clinical & Experimental Metastasis.

[45]  Sei-Hyun Ahn,et al.  Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues , 1997, Clinical & Experimental Metastasis.

[46]  R. Levy,et al.  Translocation of annexin I to plasma membranes and phagosomes in human neutrophils upon stimulation with opsonized zymosan: possible role in phagosome function. , 1996, The Biochemical journal.

[47]  E. Bröcker,et al.  Inhibition of human skin phospholipase A2 by "lipocortins" is an indirect effect of substrate/lipocortin interaction. , 1993, The Journal of investigative dermatology.

[48]  A. Ullrich,et al.  Annexin I is phosphorylated in the multivesicular body during the processing of the epidermal growth factor receptor , 1993, The Journal of cell biology.

[49]  R. Flower,et al.  Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[51]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[52]  G. Chang,et al.  Annexin A1 expression and its prognostic significance in human breast cancer. , 2010, Neoplasma.

[53]  J. Ajani,et al.  Expression of Annexin A1in Esophageal and Esophagogastric Junction Adenocarcinomas: Associationwith Poor Outcome , 2006 .

[54]  M. Crouch,et al.  Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. , 2004, Experimental cell research.

[55]  D. Ornstein,et al.  Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.